Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Zeitlinger

Showing results (341-350 of 352) with videos related to

Pageof 36
Sort By:
The Lancet. Infectious Diseases|May 14, 2013
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trialNina Wressnigg, Eva-Maria Pöllabauer, Gerald Aichinger, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 3, 2022
Multiparametric Prediction Models for Coronavirus Disease 2019 Vaccine Selection: Results of a Comparative Population-Based Cohort StudyDaniela Sieghart, Claudia A Hana, Helmuth Haslacher, et al.
Molecular Cancer|January 4, 2022
Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsiesThomas Dillinger, Raheleh Sheibani-Tezerji, Walter Pulverer, et al.
Iscience|October 23, 2023
Renin-angiotensin system inhibitor discontinuation in COVID-19 did not modify systemic ACE2 in a randomized controlled trialVincent Rathkolb, Marianna T Traugott, Andreas Heinzel, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|March 19, 2024
Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategyDaniela Sieghart, Claudia A Hana, Caroline Dürrschmid, et al.
Annals of the Rheumatic Diseases|March 4, 2025
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 updatePeter Nash, Andreas Kerschbaumer, Victoria Konzett, et al.
Clinical and Translational Medicine|May 6, 2022
Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled Phase 2 trialAnne Weiss, Emilie Delavenne, Carina Matias, et al.
Nature Communications|September 12, 2022
Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trialDaniel Mrak, Daniela Sieghart, Elisabeth Simader, et al.
Vaccine|May 20, 2023
VACCELERATE Site Network: Real-time definition of clinical study capacity in EuropeJon Salmanton-García, Pauline Wipfler, Paula Valle-Simón, et al.
Vaccines|December 23, 2023
The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE ConsortiumDimitrios Poulimeneas, Markela Koniordou, Dimitra Kousi, et al.
Pageof 36

Showing results (341-350 of 352) with videos related to

Sort By:
Pageof 36
The Lancet. Infectious Diseases|May 14, 2013
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trialNina Wressnigg, Eva-Maria Pöllabauer, Gerald Aichinger, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 3, 2022
Multiparametric Prediction Models for Coronavirus Disease 2019 Vaccine Selection: Results of a Comparative Population-Based Cohort StudyDaniela Sieghart, Claudia A Hana, Helmuth Haslacher, et al.
Molecular Cancer|January 4, 2022
Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsiesThomas Dillinger, Raheleh Sheibani-Tezerji, Walter Pulverer, et al.
Iscience|October 23, 2023
Renin-angiotensin system inhibitor discontinuation in COVID-19 did not modify systemic ACE2 in a randomized controlled trialVincent Rathkolb, Marianna T Traugott, Andreas Heinzel, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|March 19, 2024
Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategyDaniela Sieghart, Claudia A Hana, Caroline Dürrschmid, et al.
Annals of the Rheumatic Diseases|March 4, 2025
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 updatePeter Nash, Andreas Kerschbaumer, Victoria Konzett, et al.
Clinical and Translational Medicine|May 6, 2022
Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled Phase 2 trialAnne Weiss, Emilie Delavenne, Carina Matias, et al.
Nature Communications|September 12, 2022
Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trialDaniel Mrak, Daniela Sieghart, Elisabeth Simader, et al.
Vaccine|May 20, 2023
VACCELERATE Site Network: Real-time definition of clinical study capacity in EuropeJon Salmanton-García, Pauline Wipfler, Paula Valle-Simón, et al.
Vaccines|December 23, 2023
The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE ConsortiumDimitrios Poulimeneas, Markela Koniordou, Dimitra Kousi, et al.
Pageof 36